{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-010775","form_type":"8-K","ticker":"DCTH","cik":"0000872912","company_name":"DELCATH SYSTEMS, INC.","filed_at":"2025-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.566225+00:00","generated_at":"2026-05-25T08:25:09.639887+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Delcath Q4 revenue $15.1M, positive adjusted EBITDA; FY revenue $37.2M, no debt","bullets":["Q4 total revenue $15.1M ($13.7M HEPZATO US, $1.4M CHEMOSAT Europe); FY total $37.2M.","Q4 net loss narrowed to $3.4M from $11.1M; FY net loss $26.4M from $47.7M.","Q4 non-GAAP adjusted EBITDA positive $4.6M; FY adjusted EBITDA loss $2.5M.","Year-end cash & investments $53.2M; no debt; warrant exercises generated $41.3M in 2024.","16 active US centers; FDA clearance for Phase 2 HEPZATO trial in mCRC; NCCN update recommends HEPZATO for mUM."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-010775","json":"https://secwatch.observer/filing/0001628280-25-010775.json","markdown":"https://secwatch.observer/filing/0001628280-25-010775.md","text":"https://secwatch.observer/filing/0001628280-25-010775.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872912/000162828025010775/0001628280-25-010775-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872912/000162828025010775/dcth-20250306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T08:25:09.639887+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}